What is the current valuation of the US cell line-development market?

The market valuation was $1990.0 Million in 2024. Read More

What is the projected market size for the US cell line-development market by 2035?

The projected valuation for 2035 is $7008.68 Million. Read More

What is the expected CAGR for the US cell line-development market during the forecast period 2025 - 2035?

The expected CAGR is 12.13% during the forecast period. Read More

Which application segment had the highest valuation in 2024?

The Bioproduction segment had the highest valuation at $2100.0 Million. Read More

What are the key players in the US cell line-development market?

Key players include Thermo Fisher Scientific, Merck KGaA, Lonza Group, and GE Healthcare. Read More

Which type of cell lines is projected to dominate the market by 2035?

Continuous Cell Lines are projected to dominate with a valuation of $2500.0 Million. Read More

What was the valuation of the Drug Discovery segment in 2024?

The Drug Discovery segment was valued at $1400.0 Million in 2024. Read More

Which end user segment is expected to show significant growth by 2035?

Pharmaceutical Companies are expected to show significant growth, reaching $2200.0 Million. Read More

What was the valuation of the Quality Control process in 2024?

The Quality Control process was valued at $490.0 Million in 2024. Read More

How does the projected growth of the US cell line-development market compare to its past performance?

The market is expected to grow from $1990.0 Million in 2024 to $7008.68 Million by 2035, indicating robust growth. Read More

US Cell Line Development Market

US Cell Line Development Market Research Report: Size, Share, Trend Analysis By Applications (Drug Discovery, Bioproduction, Toxicity Testing, Stem Cell Research, Genetic Engineering), By Types (Hybridoma Cell Lines, Recombinant Cell Lines, Continuous Cell Lines, Primary Cell Lines), By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutions, Contract Research Organizations) and By Process (Cell Line Development, Cell Line Banking, Characterization, Quality Control) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

12.13%

2024 Market Size

$ 1,990 Million

2035 Market Size

$ 7,008.68 Million

Medical Device ● Updated April 2026 Report ID: MRFR/MED/48058-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Application (USD Million)
  1. 4.1.1 Drug Discovery
  2. 4.1.2 Bioproduction
  3. 4.1.3 Toxicity Testing
  4. 4.1.4 Stem Cell Research
  5. 4.1.5 Genetic Engineering
2. 4.2 Life Sciences, BY Type (USD Million)
  1. 4.2.1 Hybridoma Cell Lines
  2. 4.2.2 Recombinant Cell Lines
  3. 4.2.3 Continuous Cell Lines
  4. 4.2.4 Primary Cell Lines
3. 4.3 Life Sciences, BY End User (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Academic Research Institutions
  4. 4.3.4 Contract Research Organizations
4. 4.4 Life Sciences, BY Process (USD Million)
  1. 4.4.1 Cell Line Development
  2. 4.4.2 Cell Line Banking
  3. 4.4.3 Characterization
  4. 4.4.4 Quality Control
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Lonza Group (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GE Healthcare (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sartorius AG (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Boehringer Ingelheim (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Promega Corporation (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Corning Incorporated (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Charles River Laboratories (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY PROCESS
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY PROCESS, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY PROCESS, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY PROCESS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Application (USD Million, 2025-2035)

Drug Discovery
Bioproduction
Toxicity Testing
Stem Cell Research
Genetic Engineering

Life Sciences By Type (USD Million, 2025-2035)

Hybridoma Cell Lines
Recombinant Cell Lines
Continuous Cell Lines
Primary Cell Lines

Life Sciences By End User (USD Million, 2025-2035)

US Cell Line Development Market Companies
Biotechnology Companies
Academic Research Institutions
Contract Research Organizations

Life Sciences By Process (USD Million, 2025-2035)

Cell Line Development
Cell Line Banking
Characterization
Quality Control

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”